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Abstract
Purpose NF-κB signaling is critically important for regula-
tion of both innate and adaptive immune responses. While
activation of NF-κB has been implicated in malignancies such
as leukemia and lymphoma, loss-of-function mutations affect-
ing different NF-κB pathway components have been shown to
cause primary immunodeficiency disorders. Recently,
haploinsufficiency of NF-κB1 has been described in three
families with common variable immunodeficiency (CVID).
Methods and Results We studied a patient with recurrent re-
spiratory infections and bacterial parapharyngeal abscess.
Immunological investigations revealed normal total B- cell
numbers, but hypogammaglobulinemia, decreased frequen-
cies of class-switched B cells and impaired T-cell prolifera-
tion. Targeted next-generation sequencing using a custom-
designed panel comprising all known PID genes (IUIS 2014
classification) and novel candidate genes identified a novel
heterozygous frameshift mutation in the NFKB1 gene leading
to a premature stop codon (c.491delG; p.G165A*31). We
could show that the mutation leads to reduced phosphoryla-
tion of p105 upon stimulation, resulting in decreased protein
levels of p50. The further disease course was mainly charac-
terized by two episodes of severe EBV-associated lymphopro-
liferative disease responsive to rituximab treatment. Due to
disease severity, the patient is considered for allogeneic hema-
topoietic stem cell transplantation. Interestingly, the father
carries the same heterozygous NFKB1 mutation and also
shows decreased frequencies of memory B cells but has a
much milder clinical phenotype, in line with a considerable
phenotypic disease heterogeneity.
Conclusions Deficiency of NF-κB1 leads to immunodeficien-
cy with a wider phenotypic spectrum of disease manifestation
than previously appreciated, including EBV lymphoprolifera-
tive diseases as a hitherto unrecognized feature of the disease.
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Introduction
NF-κB signaling is a complex, conserved pathway critical for
regulation of both innate and adaptive immune reactions in
response to various stimuli. Central players in this pathway in
mammals comprise five transcription factors, including REL-
A/p65, REL-B, c-REL, NF-κB1/p50, and NF-κB2/p52 [1].
These transcription factors share a Rel homology domain
(RHD) in their N-terminal DNA-binding domain responsible
for formation of homo- and heterodimers which can bind to
DNA to regulate target gene expression [1].
NF-κB signaling cascades are differentiated into two major
subsets termed Bcanonical^ and Bnon-canonical^ pathways.
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Canonical NF-κB signaling may be activated upon contact
with numerous inflammatory stimuli including pattern recog-
nition receptors and cytokine receptors and signals through a
complex consisting of IKKα/IKKβ/IKKγ and the formation
of p50/p65 heterodimers (reviewed in [2]). By contrast, non-
canonical NF-κB signaling is activated through tumor necro-
sis family receptors upon binding of BAFF, lymphotoxinβ, or
CD40 ligand, and is predominantly known to regulate im-
mune cell differentiation and also formation of secondary
lymphoid organs (reviewed in [3]). Notably, recent studies
have demonstrated considerable cross talk between both arms
of NF-κB signaling; thus, these signaling cascades are highly
interconnected [4].
In view of the central role of NF-κB signaling for multiple
processes in both innate and adaptive immunity, it is not sur-
prising that aberrant NF-κB signaling may be implicated in
human disease pathogenesis. Thus, while excessive activation
of NF-κB has been shown to play a role in hematological
malignancies [5], loss-of-function mutations in genes of the
canonical and non-canonical NF-κB pathway have been asso-
ciated with distinct types of primary immunodeficiency disor-
ders including deficiencies of NEMO [6] or IKKβ [7] and
BAFF receptor [8], CD40/CD40 ligand [9, 10], NIK [11],
AID [12], or autosomal dominant mutations affecting
NFκB2 [13, 14], respectively.
Very recently, haploinsufficiency of NF-κB1 has been
identified as a novel genetic etiology of a subtype of common
variable immunodeficiency (OMIM616576) [15]. The gene
encodes for the p105 protein which is processed to the
Bactive^ p50 subunit implicated in the canonical NF-κB path-
way. As p50 lacks a C-terminal transcription activation do-
main, p50 can only activate transcription by formation of het-
erodimers, for example with REL-A, while p50 homodimers
act as transcriptional repressors [16].
Here, we identify a novel mutation of NFKB1 in a patient
with combined immunodeficiency with impaired B and T cell
functions and presentation with severe Epstein-Barr virus
(EBV)-associated lymphoproliferation as a hitherto unrecog-
nized clinical disease manifestation.
Methods
Patients
All patient material was obtained in accordance with the
Declaration of Helsinki. The study was approved by the ethics
committee of the Medical University of Vienna.
DNA Isolation and Preparation
Genomic DNA (gDNA) was isolated from EDTA blood using
an adapted protocol of the Wizard® Genomic DNA
Purification Kit (Promega). gDNA isolation from buccal
swabs was performed using the QIAamp® DNA Mini Kit
(Qiagen), following the spin protocol of the QIAamp®
DNA Mini and Blood Mini Handbook.
For library preparation, gDNAwas diluted and then mea-
sured on a Qubit 2.0 Fluorometer (Invitrogen/Life
Technologies) for a total concentration of 200 ng.
Targeted Exome Sequencing
The patient sample was screened for disease-causing variants
by a custom-designed targeted enrichment approach
(HaloPlex™/Agilent Technologies) followed by next-
generation sequencing on a HiSeq3000 (Illumina) platform
as described previously [17]. In brief, enrichment of the
targeted plus 25-bp flanking region was accomplished using
the HaloPlex Target Enrichment System (Agilent
Technologies Inc., 2013), based on a molecular inversion
probe strategy. Library preparation was performed according
to the manufacturer’s instruction. In brief, 200 ng of gDNA
was digested by eight pairs of restriction enzymes, followed
by bar code indexing and hybridization to custom-designed
capture probes for 16 h at 54 °C. Thereafter, the circularized
biotinylated target-probe complexes were extracted using
magnetic streptavidin beads. The final steps included nick
ligation, PCR library amplification, and AmPure XP bead
(Beckman Coulter, Inc.) purification prior to qualitative and
quantitative assessment of the DNA library using a 2100
Bioanalyzer instrument (Agilent). Next-generation sequenc-
ing was performed in a 150-bp paired-end mode using a
HiSeq3000 (Illumina) platform.
Data Analysis
The gross data analysis pipeline included adapter trimming of
Illumina sequences (Trimmomatic), Burrows-Wheeler
Aligner (BWA) for sequence alignment to the human genome
19 (hg19), Indel Realignment on both sequence aliquot and
sample level via Genome Analysis Toolkit (GATK; Broad
Institute), Base Quality Score Recalibration (GATK),
Haplotype Calling (GATK), and Variant Annotation
(SnpEFF, GATK). Thereafter, variant filtering included the
criteria of being rare (MAF ≤ 0.01), non-synonymous, and
within the coding region of the targeted genes. In addition to
published data, we assessed the potential relevance of variants
by recurrence within ExAC browser (Exome Aggregation
Consortium Cambridge) and in our internal dataset compris-
ing of more than 300 sequenced individuals to date. Of note,
variants with a VQSLOD score (the log odds of being a true
variant versus being false) below 99.9 % of the truth set of a
trained Gaussian mixture model can be considered as false
positives and are thus not shown herein.
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Coverage
The GATK CallableLoci tool was executed in order to assess
the proportion of callable bases, as determined by sequencing
depth and mapping quality per interrogated position. Hence,
targeted genomic regions were assigned different quality cat-
egories (pass, no coverage, low coverage, excessive coverage,
poor mapping quality) and summarized in a BED file.
According to this analysis, 99.76 % of enriched exonic bases
were considered callable with a minimum read depth of 4 and
minimum mapping quality score of 10.
Variant Validations
Sanger validation was performed according to standard capil-
lary sequencing protocol using a 3130xl Genetic Analyzer
instrument.
Flow Cytometry-Based Immunophenotyping and T Cell
Proliferation Assays
These analyses were carried out as described previously [18].
Western Blot Analysis
Following 3 h of starvation in IMDM without FCS, EBV-
transformed B lymphocytes derived from the affected individ-
ual and the father, both harboring the heterozygous NFKB1
c.491delG mutation, as well as from a healthy donor individ-
ual, were stimulated with 50 ng/ml PMA plus 1 μg/ml
ionomycin (both from Sigma Aldrich) for 30 and 60 min, as
indicated. Cells were lysed on ice (lysis buffer 20 mM Tris–
HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 μM Na3VO4,
50 mM NaF, 1 % Triton X-100; Protease Inhibitor Cocktail)
and total protein concentrations determined via Bradford
(Biorad). Fifty micrograms per sample were loaded and pro-
tein size fractionated using a 12 % polyacrylamide gel.
Proteins were transferred onto a PVDF (GEHealthcare) mem-
brane (0.45-μm pore size) overnight at 4 °C (200 mA) in
accordance with standard Western blotting protocols. P105
and p50 proteins were detected using a rabbit antibody raised
against the NF-κB1 N-terminus (no. 3035, Cell Signaling,
New England Biolabs); phosphorylated p105 (Ser933) was
detected using a monoclonal rabbit antibody (no. 4806, Cell
Signaling). GAPDH served as loading control and was detect-
ed using a mouse monoclonal antibody (sc-365062; Santa
Cruz). Anti-rabbit secondary antibody (Biorad) and anti-
mouse secondary antibody (BD Biosciences) coupled to
horseradish-peroxidase were used for signal detection.
Immunoreactive bands were visualized with Amersham
ECL Select Western Blotting Substrate (GE Healthcare).
Results
The index patient was born to non-consanguineous parents of
Caucasian origin. Following an unremarkable first year of life,
she started to have recurrent mainly upper respiratory tract
infections in early childhood. At 5 years of age, tonsillectomy
and adenotomy were performed. In the following years, the
patient suffered from recurrent upper airway infections which
were mostly self-limiting.
At the age of 15 years, she was referred to our hospital for
the first time with fever and problems with swallowing and
was found to have parapharyngeal abscess (Fig. 1a) and cer-
vical lymphadenopathy. Blood results showed leukopenia
(1.89 G/l), neutropenia (0.06 G/l), thrombocytopenia (mini-
mum 119 G/l), and elevated C-reactive protein levels (CRP;
174 mg/l). No hepatosplenomegaly was apparent. The
parapharyngeal abscess was surgically drained; histological
evaluation revealed chronic abscess-forming inflammation,
microbiologic culture infection with viridans group strepto-
cocci and actinomyces. Decreased leukocyte and thrombocyte
counts prompted bone marrow aspiration, which revealed pre-
dominantly immature granulopoesis, compatible with bacteri-
al infection, but no evidence of myelodysplasia or malignant
disease. The patient improved with antibiotic therapy and ab-
solute neutrophil counts normalized concomitantly.
Immunological investigations following recovery revealed
low absolute numbers of CD19+ B cells with reduced non-
switched and switched memory cells (IgD+/CD27+; IgD−/
CD27+) and low immunoglobulin levels (Fig. 1b, c and
Table 1). Absolute numbers of T cells were normal; however,
proliferation assays revealed impaired T-cell function in re-
sponse to tetanus toxoid, CD3, and PMA with normal re-
sponse to PHA (Table 1). The patient was started on intrave-
nous and subsequently subcutaneous immunoglobulin substi-
tution. Absolute neutrophil counts and thrombocytes were re-
peatedly decreased (thrombocytes with a minimum of 32 G/l)
with spontaneous normalization; however, anti-granulocyte
and anti-thrombocyte antibodies were negative. Few months
later, she developed fever, neutropenia (0.1 G/l), elevated CRP
(80 mg/l), esophagitis, cervical, axillary and supraclavicular
lymphadenopathy, and mild hepatosplenomegaly. Axillary
lymph node biopsy showed reactive changes and the patient
improved with antibiotic therapy.
In the following years, the patient had three to four
uncomplicated infections per year (sinusitis, pharyngitis,
urinary tract infection). She complained of intermittent
arthralgia; autoantibodies were repeatedly negative (rheu-
matoid factor (RF), anti-neutrophil cytoplasmatic antibody
(ANCA), anti-cardiolipin antibodies, anti-nuclear antibody
(ANA)). At the age of 18 years, splenomegaly (21 cm)
with multiple hypodense changes, hepatomegaly
(20 cm), and generalized lymphadenopathy occurred (not
shown). Blood results showed reactivation of Epstein-
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Barr-virus (EBV) with 1.2 × 10E3 copies/ml. Within a
short time, the patient deteriorated with high fever, elevat-
ed CRP (50 mg/l), and increasing hepatosplenomegaly and
lymphadenopathy (liver 22 cm, spleen 26 cm; Fig. 1d).
Fur ther inves t iga t ions were not susp ic ious for
macrophage-activating syndrome. With rising EBV load
(maximum 3.1 × 10E3 copies/ml), EBV-associated lym-
phoproliferative disease (EBV-LPD) was suspected. The
patient was started on corticosteroid treatment (1 mg/kg)
and weekly rituximab (375 mg/m2) was administered four
times. Prompt clinical improvement was noted, EBV load
turned negative, and CD19+ B cells were not detectable
for 8 months (Fig. 2a). However with reemergence of pe-
ripheral blood B cells, a similar clinical picture with fever,
lymphadenopathy, and hepatoslenomegaly reoccured and
reactivation of EBV (maximal load 1.2 × 10E2 copies/ml)
was detected. The patient was started on cortisone and
four courses rituximab, which has led to remission of the
disease again. In view of the relatively severe disease
course, HLA typing of the patient and family has been
initiated to prepare for allogeneic hematopoietic stem cell
transplantation. On inquiry of the patient’s family, the pa-
tient’s father declared he had been suffering from frequent
non-severe respiratory tract infections but not requiring
regular medical attention.
Identification of Underlying Genetic Defect in NFKB1
Given the unclear origin of immunodeficiency, we assessed
the patient using our custom-designed next-generation se-
quencing (NGS)-based panel which covers 419 genes, includ-
ing all known primary immunodeficiency disease (PID)-caus-
ing genes according to the IUIS classification from 2014 [19]
and several PID candidate genes in which defects are likely to
be causative for monogenic primary immunodeficiencies. Our
sequencing approach yielded very high on-target coverage
(Fig. 2b). The analysis of this patient did not reveal any ho-

















Fig. 1 Clinical and immunological phenotype. Initially, the index patient
presented with a parapharyngeal abscess which was surgically drained
(a). Immunological assessment revealed normal total number of B cells
(b) but decreased numbers of non-switched (CD27+IgD+) and switched
(CD27+IgD−) memory B cells in comparison to healthy donor. c At the
age of 18 years, the patient showed EBV lymphoproliferative diseases
including EBV reactivation, cervical lymphadenopathy (d),
splenomegaly (e), and multiple splenic lesions (f), all of which
normalized upon treatment with anti-CD20 (rituximab)
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(Supplementary Table 1), we could, however, identify a novel
frameshift mutation in NFKB1 (ENST00000226574
c.491delG; p.G165A*31), which resides within the N-
terminal RHD and results in a premature stop codon. While
the mother and sister were wild type at this position, genetic
analysis revealed the same NFKB1 mutation in the patient’s
father as in our index patient (Fig. 2c), however, associated
with a mild clinical phenotype. While his absolute numbers of
CD19+ B cells were mildly elevated (0.89 × 10E9/l), switched
memory B cells (IgD+/CD27+ 49.9 %; IgD−/CD27+ 1.05 %)
as well as IgG (including subclasses IgG1 and IgG3) and IgA
were decreased. T cell proliferation assays revealed decreased
response to T cell recall antigens such as tetanus toxoid, how-
ever not as pronounced as in the index patient, while T cell
responses to stimulation with PHA, PMA, or anti-CD3 were
normal. Despite a previous immunization, vaccination titers to
diphtheria toxin were low, comparable with the index patient’s
results (Table 1).
Western blot analysis revealed detectable but severely de-
creased levels of p50 in both the index patient (II-1) and her
Table 1 Laboratory findings
Lymphocyte subsets Patient’s father
Test date 04/2012 10/2012 11/2013 02/2015 04/2015 05/2015 10/2015 02/2016
CD3 absolute ×10E9/l (0.8–3.5) 1 1.2 1.28 0.94 0.84 0.83 0.84 1.72
CD4 absolute ×10E9/l (0.4–2.1) 0.42 0.5 0.61 0.66 0.45 0.39 0.55 0.92
CD8 absolute ×10E9/l (0.2–1.2) 0.49 0.5 0.55 0.23 0.34 0.38 0.25 0.8
CD4/8 (0.9–3.4) 0.9 1 1.11 2.91 1.34 1.03 2.19 1.15
DNT (a/b+/CD4−/CD8−) ND 2 ND 5 ND 2 2 ND
CD45RA % 54 52 43 18 27 ND ND 39
CD45R0+ memory % 23 26 40 77 67 ND ND 36
CD19 absolute ×10E9/l (0.2–0.6) 0.08 0.06 0.05 0.02 0a 0a 0.01a 0.89
IgD+/CD27+ % CD19+ (6.1–16.9) 3.5 ND 7.7 ND ND ND ND 49.9
IgD−/CD27+ % CD19+ (4.1–18.7) 0.9 ND 3.8 ND ND ND ND 1.05
CD56/CD3− absolute ×10E9/l
(0.07–1.2)
0.15 0.1 0.17 0.04 0.09 0.09 0.1 0.28
Blood counts
Test date 01/2012 02/2012 08/2012 11/2013 02/2015 04/2015 10/2015 02/2016
WBC (G/l) (4–12) 1.11 3.7 2.3 2.5 2.3 4 2.1 9.9
ALC (G/l) (0.8–3.5) 0.7 1.08 1.18 1.58 1.04 0.96 0.97 3.07
ANC (G/l) (1.9–8.00) 0.1 1.98 0.68 0.3 0.97 2.8 0.99 6.24
Thrombocytes (G/l) (140–400) 119 193 97 147 115 225 70 237
T cell proliferation
Test date 04/2012 03/2014
Stimulus PMA PHA CD3 Ab Tetanus toxoid PMA PHA CD3 Ab Tetanus toxoid
Patient (×10E3 cpm) 9 88 68 4 15 83 51 2
Healthy control (×10E3 cpm) 34 66 146 29 22 108 72 31
12/2015
Patient’s father (×10E3 cpm) 259 288 184 23
Healthy control (×10E3 cpm) 53 156 93 75
Vaccination titers Tetanus Diphteria Haemophilus
influenzae B
Pneumococcus
Patient (test date 04/2012) 0.5 IU/ml 0.04 IU/ml 0.34 μg/l 33.88 mg/l
Patient’s father (test date 02/2016) 1.7 IU/ml 0.04 IU/ml 2.04 μg/l ND
IgG IgG1 IgG2 IgG3 IgG4 IgM IgA
Immunoglobulins (mg/dl) (700–1600) (280–800) (115–570) (24–125) (5.2–125) (40–230) (70–400)
Patient (test date 03/2012) 232 148 61 22 0.3 1.2 0.05
Patient’s father (test date 02/2016) 409 165 204 18 20 41 23
Values in brackets show reference ranges. Abnormal values are printed in italic
WBC white blood cells, ALC absolute lymphocyte count, ANC absolute neutrophil count, PMA phorbol-12-myristate-13-acetate, PHA phytohemag-
glutinin, Ab antibody
a Post four cycles of rituximab
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father (I-2). Upon stimulation with PMA and ionomycin, we
observed that phosphorylation of p105 was markedly lower
than in a healthy control in line with a signaling defected
conferred by the NFKB1 mutation detected in both the index
patient and her father (Fig. 2d). No truncated p50 protein was
detected (Supplementary Figure 1).
Discussion
Identification of the genetic etiologies underlying primary im-
munodeficiencies has contributed considerably to our under-
standing of core signaling processes in the human immune
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Fig. 2 Identification of a disease-causing mutation in. Disease severity
and complications increased over time with two severe episodes of EBV-
associated lymphoproliferation within one year (a). The patient was
assessed using a targeted, next-generation sequencing-based gene panel
with high on-target coverage (b). A heterozygous mutation in the RHD
domain of the NFKB1 gene was identified, leading to a frameshift and a
subsequent stop codon (c.491delG; p.G165A*31). The patient’s father
was found to be a carrier of the disease (c) and shows an aberrant B cell
immunophenotype despite his mild clinical manifestation (Table 1). The
mutation leads to reduced phosphorylation of p105 upon stimulation in
both index patient (II-1) and father (I-2), resulting in decreased protein
levels of p50 (d)
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accelerated disease gene discovery for rare monogenetic dis-
orders altogether [20]. While historically large pedigrees were
necessary to identify novel causative gene defects and the
majority of identified defects were inherited in an autosomal
recessive manner (in part because studies in consanguineous
pedigrees were used to identify underlying gene defects),
more recently, an increasing number of autosomal dominant
(AD) PIDs has been discovered, including such that work
through AD gain-of-function mutations (e.g., activated
PIK3δ syndrome [21–24]) or haploinsufficiency (e.g.,
CTLA4 haploinsufficiency syndrome [25, 26]).
Recently, haploinsufficiency of the NF-κB subunit p50
has been described in three families [15]. Mutations were
located within the RHD domain and lead to altered or
absent p50 protein. Clinically, the patients mainly pre-
sented with recurrent respiratory tract infections, lymph-
adenopathy, and chronic-obstructive pulmonary disease,
with marked disease severity. Laboratory findings includ-
ed hypogammaglobulinemia and abnormal response to
immunizations in some patients but normal numbers
and function of T cells at least in some patients, in line
with a diagnosis of common variable immunodeficiency
[15].
Here, we describe a young adult patient with a novel frame-
shift mutation in NFKB1, also residing within the RHD.
Clinically, our patient initially had a fairly mild disease course
during childhood but then increasingly suffered from upper
respiratory tract infections. The immunological investigations,
prompted by diagnosis of a parapharyngeal abscess with un-
common microbes, demonstrated hypogammaglobulinemia
with paucity of class-switched B cells and impaired generation
of antibodies upon vaccination, but also impaired T-cell pro-
liferative responses, suggestive of a picture of combined im-
munodeficiency. The functional impairment of T cells likely
underlies the susceptibility to EBV-induced lymphoprolifera-
tion, which is a hitherto unrecognized feature of NF-κB1
haploinsufficiency. Several immunodeficiency disorders asso-
ciated with EBV lymphoproliferation have been described,
including deficiency of ITK, XIAP, STK4, SH2D1A, and
CD27 [27–30]. The coding sequences of these genes were
fully covered, and no mutations were detected in our targeted
NGS panel (Supplementary Table 2). A defective function of
Tand NK cells is thought to lead to immune dysregulation and
lymphoproliferation [30]. While absolute numbers of T cells
were normal in our patient, T-cell proliferation assays showed
markedly decreased results possibly contributing to EBV lym-
phoproliferation. Haploinsufficiency of NF-κB1 has been de-
scribed so far as a predominant defect of B cells and has been
assigned to the group of CVID. In view of the diminished
function of T cells in our patient and the severe EBV lympho-
proliferative disease, we suggest that haploinsufficiency of
NF-κB1 may cause a phenotype of combined immunodefi-
ciency at least in some patients.
Autosomal dominant inherited immunodeficiencies are of-
ten associated with incomplete disease penetrance and hetero-
geneity of clinical and laboratory manifestations. It seems that
this also applies to haploinsufficiency of NF-κB1 as our pa-
tient’s father carries the same NFKB1 mutation as the index
patient, however associated with milder clinical and laborato-
ry findings. In view of the disease heterogeneity, therapeutic
implications cannot be uniform and need to be adapted to the
presentation of the individual patient. In our index patient,
disease severity and complications increased over time with
two severe episodes of EBV-associated lymphoproliferation
within one year. Hence, we are currently considering the pa-
tient for allogeneic hematopoietic stem cell transplantation.
Comprehensive studies with larger numbers of NFKB1 mu-
tant patients are urgently needed to exhibit the full spectrum of
clinical disease manifestations of NF-κB1 haploinsufficiency,
identify potential genotype-phenotype correlations, and ratio-
nally define criteria for treatment in specific patients and
circumstances.
Conclusions
NF-κB1 haploinsufficiency is a primary immunodeficiency
resulting in impaired function of B cells and can, at least in
some patients, lead to decreased function of T cells as well.
The clinical phenotype of NF-κB1 haploinsufficiency may be
more complex with a more heterogeneous clinical disease
pattern than previously described, including EBV-associated
lymphoproliferation as a previously unrecognized clinical fea-
ture of the disease. Future studies will need to delineate the full
clinical and immunological disease spectrum and prospective-
ly assess different therapeutic approaches.
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